Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alberto Pappo, MD
St. Jude Children's Research Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University
Palo Alto, California, United States
Raya Saab, MDRecruiting - St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
Recruiting - Cook Children'S Medical Center
Fort Worth, Texas, United States
Karen AlbrittonNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Mar 2024
- Primary completion
- 31 Oct 2034
- Completion
- 31 Oct 2037
- Last update posted
- 15 Jun 2026
- Registered enrollment
- 135
- Registry id
- NCT06023641
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.